Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263). NICE guidance, August 2012.
http://guidance.nice.org.uk/TA263
NICE does not recommend bevacizumab in combination with capecitabine as first-line treatment for metastatic breast cancer when other chemotherapy (including drugs known as taxanes or anthracyclines) is not appropriate, or taxanes or anthracyclines have been given in the past 12 months.
